Initial results suggest a promising effect of CAR-T-EGFR-IL13Ra2 cell therapy in GBM and combining it with immune checkpoint blockade (ICB) may lead to significant tumor regression and improved overall survival [49]. The gene discussed is IL13RA2; the disease is glioblastoma.